These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37405389)

  • 41. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Tortelli R; Galizia I; Prete C; Daniele A; Pilotto A; Greco A; Logroscino G
    Immunotherapy; 2016 Sep; 8(9):1119-34. PubMed ID: 27485083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.
    Pasinetti GM; Ksiezak-Reding H; Santa-Maria I; Wang J; Ho L
    J Neurochem; 2010 Sep; 114(6):1557-68. PubMed ID: 20569300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
    Boxer AL; Qureshi I; Ahlijanian M; Grundman M; Golbe LI; Litvan I; Honig LS; Tuite P; McFarland NR; O'Suilleabhain P; Xie T; Tirucherai GS; Bechtold C; Bordelon Y; Geldmacher DS; Grossman M; Isaacson S; Zesiewicz T; Olsson T; Muralidharan KK; Graham DL; O'Gorman J; Haeberlein SB; Dam T
    Lancet Neurol; 2019 Jun; 18(6):549-558. PubMed ID: 31122495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
    Holland N; Malpetti M; Rittman T; Mak EE; Passamonti L; Kaalund SS; Hezemans FH; Jones PS; Savulich G; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2022 Mar; 145(1):340-348. PubMed ID: 34398211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imaging biomarkers in tauopathies.
    Dani M; Edison P; Brooks DJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S26-8. PubMed ID: 26299160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
    Ayalon G; Lee SH; Adolfsson O; Foo-Atkins C; Atwal JK; Blendstrup M; Booler H; Bravo J; Brendza R; Brunstein F; Chan R; Chandra P; Couch JA; Datwani A; Demeule B; DiCara D; Erickson R; Ernst JA; Foreman O; He D; Hötzel I; Keeley M; Kwok MCM; Lafrance-Vanasse J; Lin H; Lu Y; Luk W; Manser P; Muhs A; Ngu H; Pfeifer A; Pihlgren M; Rao GK; Scearce-Levie K; Schauer SP; Smith WB; Solanoy H; Teng E; Wildsmith KR; Bumbaca Yadav D; Ying Y; Fuji RN; Kerchner GA
    Sci Transl Med; 2021 May; 13(593):. PubMed ID: 33980574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent developments with tau-based drug discovery.
    Iqbal K; Liu F; Gong CX
    Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tau immunotherapy for Alzheimer's disease.
    Pedersen JT; Sigurdsson EM
    Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies.
    de Silva R; Lashley T; Gibb G; Hanger D; Hope A; Reid A; Bandopadhyay R; Utton M; Strand C; Jowett T; Khan N; Anderton B; Wood N; Holton J; Revesz T; Lees A
    Neuropathol Appl Neurobiol; 2003 Jun; 29(3):288-302. PubMed ID: 12787326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.
    Piras A; Collin L; Grüninger F; Graff C; Rönnbäck A
    Acta Neuropathol Commun; 2016 Mar; 4():22. PubMed ID: 26936765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four-repeat tauopathies.
    Rösler TW; Tayaranian Marvian A; Brendel M; Nykänen NP; Höllerhage M; Schwarz SC; Hopfner F; Koeglsperger T; Respondek G; Schweyer K; Levin J; Villemagne VL; Barthel H; Sabri O; Müller U; Meissner WG; Kovacs GG; Höglinger GU
    Prog Neurobiol; 2019 Sep; 180():101644. PubMed ID: 31238088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.
    Villemagne VL; Okamura N
    Curr Opin Neurobiol; 2016 Feb; 36():43-51. PubMed ID: 26397020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
    Martínez-Maldonado A; Ontiveros-Torres MÁ; Harrington CR; Montiel-Sosa JF; Prandiz RG; Bocanegra-López P; Sorsby-Vargas AM; Bravo-Muñoz M; Florán-Garduño B; Villanueva-Fierro I; Perry G; Garcés-Ramírez L; de la Cruz F; Martínez-Robles S; Pacheco-Herrero M; Luna-Muñoz J
    J Alzheimers Dis; 2021; 79(4):1517-1531. PubMed ID: 33459640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.